ArticleTheranostics2018
"Albumin Hitchhiking" with an Evans Blue Analog for Cancer Theranostics.
Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Optical imaging unveils morphological heterogeneity at the hepatic lobule level during metabolic dysfunction-associated fatty liver disease progression [Invited].Biomedical optics express · 2025Article
- Biodistribution-Driven Discovery Identifies a Glycosidase-Cleavable Linker to Reprogram Radiotheranostics.bioRxiv : the preprint server for biology · 2025Article
- Article
- The preclinical study ofAnnals of nuclear medicine · 2023Article
- [Soybean isoflavones alleviate cerebral ischemia/reperfusion injury in rats by inhibiting ferroptosis and inflammatory cascade reaction].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- Advanced hitchhiking nanomaterials for biomedical applications.Theranostics · 2023Review
- Article
- A Comparison of Evans Blue and 4-(Pharmaceutics · 2022Article
- Strategies for developing long-lasting therapeutic nucleic acid aptamer targeting circulating protein: The present and the future.Frontiers in cell and developmental biology · 2022Review
- Unsymmetrical cyanine dye via in vivo hitchhiking endogenous albumin affords high-performance NIR-II/photoacoustic imaging and photothermal therapy.Journal of nanobiotechnology · 2021Article
- Somatostatin Receptor Type 2 as an Imaging and Treatment Target for Thyroid Cancer.Radiology. Imaging cancer · 2021Article
- Article
- ImmunoPET: Concept, Design, and Applications.Chemical reviews · 2020Review
- Dose escalation of an Evans blue-modified radiolabeled somatostatin analogEuropean journal of nuclear medicine and molecular imaging · 2020Article
- Harnessing albumin as a carrier for cancer therapies.Advanced drug delivery reviews · 2018Review
- A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy.Theranostics · 2018Article
Corrections and comments
- Comment on
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Although
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.